Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
COLL

COLL - Collegium Pharmaceutical Inc Stock Price, Fair Value and News

31.97USD+0.09 (+0.28%)Market Closed

Market Summary

COLL
USD31.97+0.09
Market Closed
0.28%

COLL Alerts

  • 4 major insider sales recently.
  • Big jump in Earnings (Y/Y)

COLL Stock Price

View Fullscreen

COLL RSI Chart

COLL Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

11.21

Price/Sales (Trailing)

1.84

EV/EBITDA

3.84

Price/Free Cashflow

3.39

COLL Price/Sales (Trailing)

COLL Profitability

EBT Margin

22.92%

Return on Equity

41.99%

Return on Assets

8.37%

Free Cashflow Yield

29.46%

COLL Fundamentals

COLL Revenue

Revenue (TTM)

566.9M

Rev. Growth (Yr)

0.11%

Rev. Growth (Qtr)

-3.22%

COLL Earnings

Earnings (TTM)

93.3M

Earnings Growth (Yr)

259.03%

Earnings Growth (Qtr)

-13.23%

Breaking Down COLL Revenue

Last 7 days

0.5%

Last 30 days

-0.8%

Last 90 days

-16.2%

Trailing 12 Months

40.6%

How does COLL drawdown profile look like?

COLL Financial Health

Current Ratio

1.21

COLL Investor Care

Buy Backs (1Y)

5.43%

Diluted EPS (TTM)

2.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024566.9M000
2023524.9M536.9M546.6M566.8M
2022272.9M313.5M361.7M463.9M
2021321.2M326.1M325.8M276.9M
2020298.7M301.7M307.9M310.0M
2019291.2M293.2M295.9M296.7M
201890.1M159.6M217.8M280.4M
20177.5M13.2M19.0M28.5M
20166.8M5.1M3.4M1.7M
20150010.2M8.5M
201300012.0M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Collegium Pharmaceutical Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 03, 2024
kuhlmann shirley r.
sold
-814,180
32.5672
-25,000
evp and general counsel
May 28, 2024
tupper colleen
sold
-674,368
34.2145
-19,710
evp & chief financial officer
May 24, 2024
dreyer scott
sold
-1,930,460
33.9827
-56,807
evp & chief commercial officer
May 24, 2024
dreyer scott
acquired
571,698
24.03
23,791
evp & chief commercial officer
May 23, 2024
dreyer scott
acquired
1,230,550
24.03
51,209
evp & chief commercial officer
May 23, 2024
dreyer scott
sold
-1,732,090
33.824
-51,209
evp & chief commercial officer
May 16, 2024
mcfarlane neil f.
acquired
-
-
7,693
-
May 16, 2024
bohlin garen g
acquired
-
-
7,693
-
May 16, 2024
melincoff gwen a
acquired
-
-
7,693
-

1–10 of 50

Which funds bought or sold COLL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
reduced
-52.96
-9,064
11,744
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
87,000
416,000
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
62.08
121,578
237,578
0.03%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-11.19
135,761
1,266,460
-%
May 16, 2024
JANE STREET GROUP, LLC
added
150
834,483
1,219,880
-%
May 16, 2024
COMERICA BANK
added
62.5
498,591
973,673
-%
May 15, 2024
Petrus Trust Company, LTA
reduced
-60.22
-237,269
238,898
0.02%
May 15, 2024
GOLDMAN SACHS GROUP INC
reduced
-20.05
52,731
6,364,540
-%
May 15, 2024
Voya Investment Management LLC
reduced
-22.21
-8,239
426,282
-%
May 15, 2024
CAPTRUST FINANCIAL ADVISORS
sold off
-100
-561,243
-
-%

1–10 of 38

Are Funds Buying or Selling COLL?

Are funds buying COLL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own COLL
No. of Funds

Unveiling Collegium Pharmaceutical Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
eventide asset management, llc
8.07%
2,630,478
SC 13G/A
Feb 13, 2024
vanguard group inc
7.09%
2,312,786
SC 13G/A
Feb 12, 2024
rubric capital management lp
8.46%
2,758,253
SC 13G/A
Jan 19, 2024
blackrock inc.
17.7%
5,786,527
SC 13G/A
Feb 10, 2023
rubric capital management lp
9.93%
3,333,628
SC 13G/A
Feb 09, 2023
janus henderson group plc
4.4%
1,481,170
SC 13G/A
Feb 09, 2023
vanguard group inc
6.58%
2,208,111
SC 13G/A
Jan 30, 2023
blackrock inc.
17.1%
5,731,305
SC 13G/A
Sep 09, 2022
janus henderson group plc
5.8%
1,987,495
SC 13G/A
Feb 15, 2022
perceptive advisors llc
0%
0
SC 13G/A

Recent SEC filings of Collegium Pharmaceutical Inc

View All Filings
Date Filed Form Type Document
Jun 05, 2024
144
Notice of Insider Sale Intent
Jun 05, 2024
4
Insider Trading
Jun 04, 2024
144
Notice of Insider Sale Intent
Jun 03, 2024
144
Notice of Insider Sale Intent
Jun 03, 2024
144
Notice of Insider Sale Intent
May 30, 2024
144
Notice of Insider Sale Intent
May 29, 2024
4
Insider Trading
May 29, 2024
144/A
144/A
May 29, 2024
144
Notice of Insider Sale Intent
May 28, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Collegium Pharmaceutical Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.0B
85.6B
-3.84% -9.54%
9.1
4.09
5.68% 202.39%
327.6B
61.4B
0.70% 19.17%
142.08
5.34
6.11% -82.30%
160.0B
29.5B
-2.39% 35.63%
42.52
5.42
12.76% -52.47%
156.6B
35.0B
-2.74% -31.33%
134.79
4.47
-26.40% -92.03%
79.1B
27.4B
-4.74% -17.19%
163.34
2.88
1.51% -91.32%
19.5B
16.0B
2.01% 128.69%
-39.52
1.22
7.23% 71.10%
MID-CAP
4.2B
1.7B
0.53% -21.09%
9.66
2.43
54.01% 364.56%
3.8B
4.6B
-9.64% -15.95%
-492.88
0.83
-0.06% 94.55%
2.3B
9.0B
-11.50% -15.30%
-4.98
0.25
10.01% -27.45%
2.0B
676.2M
-4.53% -14.12%
12.84
2.94
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-11.06% 3.51%
-3.83
1.81
24.65% 80.36%
22.8M
1.3M
-1.44% -45.62%
-3.08
17.54
-98.14% -104.71%
16.7M
89.6M
-3.92% -20.33%
-1.17
0.19
287.27% -129.41%
2.5M
21.5M
-5.26% -89.97%
-0.32
0.11
66.16% 61.84%
347.8K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Collegium Pharmaceutical Inc News

Latest updates
Yahoo Finance UK10 Jun 202409:16 pm
Defense World09 Jun 202406:26 am
Yahoo Movies UK08 Jun 202407:15 am
StockNews.com16 May 202407:00 am

Collegium Pharmaceutical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-3.2%14515013713614513012712484.0027.0079.0083.0088.0076.0079.0078.0077.0074.0073.0075.0075.00
Gross Profit-3.4%91.0095.0080.0074.0077.0050.0059.0052.0048.00-1.3346.0050.0056.0044.0048.0048.0039.0025.0026.0026.0025.00
Costs and Expenses------------------77.0079.0080.0085.00
Operating Expenses27.4%42.0033.0035.0038.0053.0038.0038.0041.0059.0033.0032.0034.0034.0029.0029.0032.0034.0027.0033.0031.0035.00
  S&GA Expenses27.4%42.0033.0035.0038.0053.0038.0038.0041.0055.0027.0031.0030.0031.0027.0026.0029.0031.0025.0030.0029.0032.00
  R&D Expenses---------4.002.001.003.003.002.002.002.003.002.002.002.003.00
EBITDA Margin30.8%0.38*0.29*0.20*0.15*0.10*0.08*-0.03*-0.05*-0.04*0.07*0.21*0.23*---------
Interest Expenses-10.1%17.0019.0021.0022.0021.0021.0019.0018.006.005.005.005.006.008.008.008.005.000.000.000.000.00
Income Taxes-39.7%9.0015.008.005.00-0.13-0.591.00-1.45-2.77-13.841.00-61.85-0.190.000.000.000.00----
Earnings Before Taxes-21.6%37.0047.0029.0018.00-17.56-7.791.00-6.65-15.84-38.889.0011.0015.007.0012.008.000.00-2.20-6.11-4.71-
EBT Margin71.5%0.23*0.13*0.04*-0.01*-0.06*-0.06*-0.17*-0.17*-0.13*-0.01*0.13*0.14*---------
Net Income-13.2%28.0032.0021.0013.00-17.43-7.200.00-5.19-13.07-25.038.0073.0016.007.0011.008.000.00-2.20-6.11-4.71-9.70
Net Income Margin93.7%0.16*0.08*0.02*-0.02*-0.06*-0.05*-0.12*-0.11*0.16*0.26*0.32*0.33*---------
Free Cashflow-16.1%61.0073.0074.0010027.0065.0043.0040.00-25.4236.0017.0029.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-2.5%1,1141,1431,1781,2141,2141,1741,2011,2461,246692742714646644644647635306304302294
  Current Assets0.3%539538537537498420405410364316363319296278262251224256250245234
    Cash Equivalents-4.3%229239259284269176134123107186193203183177165146116170154149135
  Inventory-3.3%31.0032.0034.0026.0033.0047.0065.0078.0080.0017.0017.0020.0015.0016.0017.0019.0016.0010.009.0010.009.00
  Net PPE-3.3%15.0016.0017.0018.0019.0020.0020.0020.0020.0019.0020.0020.0020.0019.0018.0015.0013.0012.0012.0010.0010.00
  Goodwill0%134134134134134134130130134------------
Liabilities-5.9%8929489991,0131,0359791,0041,0481,050489491461476458471491494219220216208
  Current Liabilities-2.5%446458465435413434414415374280269227230239242252244202201196189
Shareholder's Equity13.7%22219517920118019519719819620325125317018617315614187.0084.0086.0086.00
  Retained Earnings11.9%-205-233-265-285-298-281-274-274-269-256-231-239-312-333-340-351-359-359-357-351-346
  Additional Paid-In Capital-0.1%565566546548540538526520513502500492482519513507500447442437433
Shares Outstanding2.6%33.0032.0034.0035.0034.0034.0034.0034.0034.0035.0035.0035.00---------
Float----742---600---831---599---416-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-15.5%61,93773,33874,01899,72227,67166,32542,76940,451-25,31536,19817,25429,53520,57022,57734,18043,854-6,66915,6566,06914,627-8,569
  Share Based Compensation6.8%7,4757,0027,0277,0726,0355,6705,3775,6926,1354,9125,9486,5166,8796,2105,1655,5844,9513,9664,1374,1624,263
Cashflow From Investing27.8%-18,128-25,097-3,822-41,717-176-940-113-461-572,177-515-276-725-428-1,481-2,403-2,241-367,647-889-1,351-875-3,323
Cashflow From Financing20.2%-54,146-67,826-95,413-45,23668,297-25,823-31,252-23,966517,764-42,498-26,508-8,829-11,468-12,403-12,032-12,211323,1201,41440751.00169
  Buy Backs-100.0%-25,000---7,641---------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

COLL Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues  
Total product revenues, net$ 144,923$ 144,767
Revenue from Contract with Customer, Product and Service [Extensible List]us-gaap:ProductMemberus-gaap:ProductMember
Cost of product revenues  
Cost of product revenues (excluding intangible asset amortization)$ 18,950$ 29,899
Cost, Product and Service [Extensible List]us-gaap:ProductMemberus-gaap:ProductMember
Intangible asset amortization$ 34,517$ 37,466
Total cost of product revenues53,46767,365
Gross profit91,45677,402
Operating expenses  
Selling, general and administrative41,98252,775
Total operating expenses41,98252,775
Income from operations49,47424,627
Interest expense(17,339)(21,427)
Interest income4,4872,747
Loss on extinguishment of debt (23,504)
Income (loss) before income taxes36,622(17,557)
Provision for (benefit from) income taxes8,909(131)
Net income (loss)$ 27,713$ (17,426)
Earnings (loss) per share - basic (in $ per share)$ 0.86$ (0.51)
Weighted-average shares - basic32,326,58934,319,291
Earnings (loss) per share - diluted (in $ per share)$ 0.71$ (0.51)
Weighted-average shares - diluted41,438,46634,319,291

COLL Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 228,610$ 238,947
Marketable securities89,43871,601
Accounts receivable, net174,693179,525
Inventory31,27632,332
Prepaid expenses and other current assets15,24315,195
Total current assets539,260537,600
Property and equipment, net15,45715,983
Operating lease assets5,8136,029
Intangible assets, net387,191421,708
Restricted cash1,0471,047
Deferred tax assets30,67126,259
Other noncurrent assets954825
Goodwill133,857133,857
Total assets1,114,2501,143,308
Current liabilities  
Accounts payable6,0208,692
Accrued liabilities38,19037,571
Accrued rebates, returns and discounts217,880227,331
Current portion of term notes payable183,333183,333
Current portion of operating lease liabilities1,013988
Total current liabilities446,436457,915
Term notes payable, net of current portion177,360221,713
Convertible senior notes262,425262,125
Operating lease liabilities, net of current portion5,8606,124
Total liabilities892,081947,877
Commitments and contingencies (refer to Note 14)
Shareholders' equity:  
Preferred stock, $0.001 par value; authorized shares - 5,000,000
Common stock, $0.001 par value; authorized shares - 100,000,000; 39,029,639 issued and 32,705,747 outstanding shares as of March 31, 2024 and 38,192,441 issued and 31,868,549 outstanding shares as of December 31, 20233938
Additional paid-in capital565,111565,949
Treasury stock, at cost; 6,323,892 shares as of March 31, 2024 and 6,323,892 shares as of December 31, 2023(137,381)(137,381)
Accumulated other comprehensive (loss) income(124)14
Accumulated deficit(205,476)(233,189)
Total shareholders' equity222,169195,431
Total liabilities and shareholders' equity$ 1,114,250$ 1,143,308
COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
 CEO
 WEBSITEcollegiumpharma.com
 INDUSTRYPharmaceuticals
 EMPLOYEES207

Collegium Pharmaceutical Inc Frequently Asked Questions


What is the ticker symbol for Collegium Pharmaceutical Inc? What does COLL stand for in stocks?

COLL is the stock ticker symbol of Collegium Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Collegium Pharmaceutical Inc (COLL)?

As of Wed Jun 12 2024, market cap of Collegium Pharmaceutical Inc is 1.04 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of COLL stock?

You can check COLL's fair value in chart for subscribers.

What is the fair value of COLL stock?

You can check COLL's fair value in chart for subscribers. The fair value of Collegium Pharmaceutical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Collegium Pharmaceutical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for COLL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Collegium Pharmaceutical Inc a good stock to buy?

The fair value guage provides a quick view whether COLL is over valued or under valued. Whether Collegium Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact Collegium Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for COLL.

What is Collegium Pharmaceutical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, COLL's PE ratio (Price to Earnings) is 11.18 and Price to Sales (PS) ratio is 1.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. COLL PE ratio will change depending on the future growth rate expectations of investors.